JP2011521976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521976A5 JP2011521976A5 JP2011511892A JP2011511892A JP2011521976A5 JP 2011521976 A5 JP2011521976 A5 JP 2011521976A5 JP 2011511892 A JP2011511892 A JP 2011511892A JP 2011511892 A JP2011511892 A JP 2011511892A JP 2011521976 A5 JP2011521976 A5 JP 2011521976A5
- Authority
- JP
- Japan
- Prior art keywords
- strain
- gene
- vaccine
- pora
- genetically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims description 105
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 230000002779 inactivation Effects 0.000 claims description 49
- 230000014509 gene expression Effects 0.000 claims description 35
- 101710116435 Outer membrane protein Proteins 0.000 claims description 28
- 101100203230 Neisseria meningitidis serogroup B (strain MC58) siaA gene Proteins 0.000 claims description 23
- 241000588650 Neisseria meningitidis Species 0.000 claims description 22
- 101710186862 Factor H binding protein Proteins 0.000 claims description 21
- 101150093941 PORA gene Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 238000003780 insertion Methods 0.000 claims description 20
- 230000037431 insertion Effects 0.000 claims description 20
- 230000001965 increasing effect Effects 0.000 claims description 19
- 208000037941 meningococcal disease Diseases 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 238000012239 gene modification Methods 0.000 claims description 12
- 230000005017 genetic modification Effects 0.000 claims description 12
- 235000013617 genetically modified food Nutrition 0.000 claims description 12
- 101150093628 opaD gene Proteins 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 101150031431 opa gene Proteins 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 230000003053 immunization Effects 0.000 claims description 6
- 238000002649 immunization Methods 0.000 claims description 6
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 6
- 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 5
- 230000010473 stable expression Effects 0.000 claims description 5
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 108010031133 Transferrin-Binding Protein A Proteins 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- -1 lacto-N-neotetraose tetrasaccharide Chemical class 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 206010059866 Drug resistance Diseases 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 108700026244 Open Reading Frames Proteins 0.000 claims description 2
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000009450 sialylation Effects 0.000 claims description 2
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 claims description 2
- 150000004044 tetrasaccharides Chemical class 0.000 claims description 2
- 101150076489 B gene Proteins 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 102100030386 Granzyme A Human genes 0.000 claims 1
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 241000233866 Fungi Species 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5746208P | 2008-05-30 | 2008-05-30 | |
| US61/057,462 | 2008-05-30 | ||
| PCT/US2009/045818 WO2009158142A1 (en) | 2008-05-30 | 2009-06-01 | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014250805A Division JP2015061870A (ja) | 2008-05-30 | 2014-12-11 | 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011521976A JP2011521976A (ja) | 2011-07-28 |
| JP2011521976A5 true JP2011521976A5 (enExample) | 2012-07-12 |
| JP5723768B2 JP5723768B2 (ja) | 2015-05-27 |
Family
ID=41444870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011511892A Expired - Fee Related JP5723768B2 (ja) | 2008-05-30 | 2009-06-01 | 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用 |
| JP2014250805A Withdrawn JP2015061870A (ja) | 2008-05-30 | 2014-12-11 | 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014250805A Withdrawn JP2015061870A (ja) | 2008-05-30 | 2014-12-11 | 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9387239B2 (enExample) |
| EP (1) | EP2296699A4 (enExample) |
| JP (2) | JP5723768B2 (enExample) |
| KR (1) | KR20110053314A (enExample) |
| CN (1) | CN102105166A (enExample) |
| AU (1) | AU2009262893B2 (enExample) |
| BR (1) | BRPI0913268A2 (enExample) |
| CA (1) | CA2726465A1 (enExample) |
| CO (1) | CO6341569A2 (enExample) |
| CR (1) | CR11812A (enExample) |
| DO (1) | DOP2010000364A (enExample) |
| EC (1) | ECSP10010723A (enExample) |
| IL (1) | IL209660A0 (enExample) |
| MX (1) | MX2010012999A (enExample) |
| NZ (1) | NZ589812A (enExample) |
| RU (1) | RU2477145C2 (enExample) |
| UA (1) | UA99659C2 (enExample) |
| WO (1) | WO2009158142A1 (enExample) |
| ZA (1) | ZA201008548B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU783894B2 (en) | 1999-05-19 | 2005-12-22 | Novartis Vaccines And Diagnostics S.R.L. | Combination neisserial compositions |
| GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| EP2544714A1 (en) * | 2010-03-10 | 2013-01-16 | GlaxoSmithKline Biologicals S.A. | Vaccine composition |
| RU2580620C2 (ru) | 2010-08-23 | 2016-04-10 | ВАЙЕТ ЭлЭлСи | СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086 |
| GB201015132D0 (en) * | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
| BR112013005626B1 (pt) | 2010-09-10 | 2022-07-26 | Glaxosmithkline Biologicals Sa | Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição |
| WO2012032489A1 (en) | 2010-09-10 | 2012-03-15 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
| MX2014002375A (es) * | 2011-08-31 | 2014-09-15 | Children S Hospital & Res Ct Oakland | Secuencias diseñadas para facilitar la expresion de antigenos en neisseria y metodos de uso. |
| MX2014008988A (es) * | 2012-02-02 | 2014-08-27 | Novartis Ag | Promotores para aumento de expresion de proteinas en meningococo. |
| ES2750366T3 (es) | 2012-03-08 | 2020-03-25 | Glaxosmithkline Biologicals Sa | Ensayo de potencia in vitro para vacunas meningocócicas basadas en proteína |
| CA2865745C (en) | 2012-03-09 | 2018-01-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| KR101452830B1 (ko) * | 2012-04-06 | 2014-10-21 | 아이진 주식회사 | 두 가지 항암물질을 동시에 제공하는 대장균 균주 |
| RU2662970C2 (ru) | 2012-09-18 | 2018-07-31 | Новартис Аг | Везикулы наружной мембраны |
| US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
| RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
| AU2016221318B2 (en) | 2015-02-19 | 2020-06-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| US11292808B2 (en) * | 2016-01-28 | 2022-04-05 | Intravacc B.V. | Modified hexa-acylated neisserial LPS |
| EP3263695A1 (en) * | 2016-06-29 | 2018-01-03 | GlaxoSmithKline Biologicals SA | Immunogenic compositions |
| GB201614687D0 (en) * | 2016-08-31 | 2016-10-12 | Univ Oxford Innovation Ltd | fHbp scaffold |
| HUE052751T2 (hu) * | 2016-11-25 | 2021-05-28 | Glaxosmithkline Biologicals Sa | Natív OMV-antigén konjugátumok és alkalmazásuk |
| US10183070B2 (en) | 2017-01-31 | 2019-01-22 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| CN107151270B (zh) * | 2017-03-22 | 2018-07-31 | 武汉博沃生物科技有限公司 | 重组ΔfHbp-NadA融合蛋白载体及其制备方法和应用 |
| US12502427B2 (en) | 2019-03-21 | 2025-12-23 | Lonza Sales Ag | Extracellular vesicles for vaccine delivery |
| EP4034157A1 (en) | 2019-09-27 | 2022-08-03 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| CN113151354B (zh) * | 2021-03-22 | 2022-03-08 | 中国农业科学院兰州兽医研究所 | 一种用于条件性敲除目的基因的载体及条件性敲除目的基因的方法 |
| IT202400003229A1 (it) | 2024-02-15 | 2025-08-15 | Cioccio Vito Di | Procedimento per la purificazione di omv da batteri gram-negativi, e relativi usi |
| CN119020251A (zh) * | 2024-08-26 | 2024-11-26 | 南昌大学 | 一株脂多糖修饰b群脑膜炎球菌与其外膜囊泡制备及应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4601903A (en) * | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US4727136A (en) * | 1985-10-01 | 1988-02-23 | Canadian Patents And Development Ltd. | Modified meningococcal group B polysaccharide for conjugate vaccine |
| EP0449958B9 (en) | 1988-12-19 | 2003-05-28 | American Cyanamid Company | Meningococcal class 1 outer-membrane protein vaccine |
| US7118757B1 (en) * | 1988-12-19 | 2006-10-10 | Wyeth Holdings Corporation | Meningococcal class 1 outer-membrane protein vaccine |
| DE4023721A1 (de) | 1990-07-26 | 1992-01-30 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von vakzinen und ihre verwendung |
| US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
| NL9201716A (nl) * | 1992-10-02 | 1994-05-02 | Nederlanden Staat | Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat. |
| US7112332B1 (en) * | 1992-10-08 | 2006-09-26 | The United States Of America As Represented By The Secretary Of The Army | Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides |
| DE69423383T2 (de) * | 1993-05-13 | 2000-08-24 | American Cyanamid Co., Wayne | Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken |
| US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| EP0854729B2 (en) * | 1995-09-18 | 2008-10-22 | United States Army Medical Research Materiel Command (USAMRMC) | Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines |
| US6558677B2 (en) * | 1996-10-15 | 2003-05-06 | Wendell D. Zollinger | Vaccine against gram negative bacteria |
| GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
| GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| US20030215469A1 (en) * | 1998-11-02 | 2003-11-20 | Microbiological Research Authority | Multicomponent meningococcal vaccine |
| CA2371928C (en) | 1999-02-22 | 2013-08-13 | Microbiological Research Authority | Neisserial vaccine compositions and methods |
| GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| CA2871789C (en) * | 2000-01-17 | 2017-04-04 | Novartis Vaccines And Diagnostics S.R.L. | Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins |
| NO20002828D0 (no) * | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
| DK1296715T4 (en) * | 2000-06-29 | 2016-03-07 | Smithkline Beecham Biolog | Multivalent vaccine composition. |
| GB0103170D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| GB0024200D0 (en) * | 2000-10-03 | 2000-11-15 | Smithkline Beecham Sa | Component vaccine |
| GB0103169D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| JP2004527524A (ja) * | 2001-04-05 | 2004-09-09 | カイロン コーポレイション | 非経口初回抗原刺激後の粘膜追加免疫 |
| GB0130123D0 (en) * | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
| EP1374892A1 (en) * | 2002-06-28 | 2004-01-02 | Braun, Jan Matthias, Dr. | Medicament for the treatment of diseases due to infection by Neisseria Meningitidis |
| CA2493124C (en) | 2002-08-02 | 2014-04-29 | Glaxosmithkline Biologicals S.A. | Vaccine |
| CU23377A1 (es) | 2003-11-04 | 2009-05-28 | Ct De Ingenieria Genetica Y Biotecnologia | Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes |
| JP5173194B2 (ja) * | 2003-12-23 | 2013-03-27 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| CN1997392B (zh) * | 2004-05-11 | 2011-06-01 | 荷兰健康、福利与体育部部长代表的荷兰国 | 作为佐剂的脑膜炎奈瑟氏菌lgtB LOS |
| US7537766B2 (en) * | 2004-08-30 | 2009-05-26 | Wyeth | Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof |
| GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| LT2682126T (lt) * | 2005-01-27 | 2017-02-27 | Children`s Hospital & Research Center at Oakland | Gna1870 pagrindu gaminamos pūslelių pavidalo vakcinos, skirtos plataus spektro apsaugai nuo neisseria meningitidis sukeltų ligų |
| DE602007003596D1 (de) * | 2006-06-12 | 2010-01-14 | Glaxosmithkline Biolog Sa | Impfstoff |
-
2009
- 2009-06-01 RU RU2010153658/15A patent/RU2477145C2/ru not_active IP Right Cessation
- 2009-06-01 CN CN200980125861XA patent/CN102105166A/zh active Pending
- 2009-06-01 EP EP09770677.4A patent/EP2296699A4/en not_active Withdrawn
- 2009-06-01 MX MX2010012999A patent/MX2010012999A/es unknown
- 2009-06-01 KR KR1020107029750A patent/KR20110053314A/ko not_active Ceased
- 2009-06-01 WO PCT/US2009/045818 patent/WO2009158142A1/en not_active Ceased
- 2009-06-01 US US12/995,268 patent/US9387239B2/en not_active Expired - Fee Related
- 2009-06-01 UA UAA201015812A patent/UA99659C2/uk unknown
- 2009-06-01 BR BRPI0913268A patent/BRPI0913268A2/pt not_active IP Right Cessation
- 2009-06-01 JP JP2011511892A patent/JP5723768B2/ja not_active Expired - Fee Related
- 2009-06-01 AU AU2009262893A patent/AU2009262893B2/en not_active Ceased
- 2009-06-01 NZ NZ589812A patent/NZ589812A/xx not_active IP Right Cessation
- 2009-06-01 CA CA2726465A patent/CA2726465A1/en not_active Abandoned
-
2010
- 2010-11-25 CR CR11812A patent/CR11812A/es unknown
- 2010-11-26 DO DO2010000364A patent/DOP2010000364A/es unknown
- 2010-11-29 ZA ZA2010/08548A patent/ZA201008548B/en unknown
- 2010-11-30 IL IL209660A patent/IL209660A0/en unknown
- 2010-12-27 EC EC2010010723A patent/ECSP10010723A/es unknown
- 2010-12-29 CO CO10164103A patent/CO6341569A2/es not_active Application Discontinuation
-
2014
- 2014-12-11 JP JP2014250805A patent/JP2015061870A/ja not_active Withdrawn
-
2016
- 2016-07-12 US US15/208,067 patent/US20170100471A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9707286B2 (en) | Process for detergent-free production of outer membrane vesicles of a gram-negative bacterium | |
| RU2010153658A (ru) | Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения | |
| Cox | Recombinant protein vaccines produced in insect cells | |
| US8129147B2 (en) | Meningococcal oligosaccharide linked polysaccharides and diptheria protein conjugate vaccine for all ages | |
| US20130071422A1 (en) | Adjuvanted vaccines for serogroup b meningococcus | |
| JP6582020B2 (ja) | 発酵方法 | |
| US20110262484A1 (en) | Outer membrane vesicle prime-protein boost vaccine | |
| JP2002537352A5 (enExample) | ||
| Kenny et al. | A chemically defined protein-free liquid medium for the cultivation of some species of Neisseria | |
| Henriques et al. | Mathematical modeling of capsular polysaccharide production by Neisseria meningitidis serogroup C in bioreactors | |
| NZ618918B2 (en) | A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium | |
| CN102643887A (zh) | 一种重组戊型肝炎疫苗抗原p179蛋白的发酵制备方法 |